This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA
Signal Transduction and Targeted Therapy Open Access 20 February 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Singh, A. K. et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2113380 (2021)
Singh, A. K. et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2113379 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Allison, S.J. Daprodustat for anaemia in CKD. Nat Rev Nephrol 18, 3 (2022). https://doi.org/10.1038/s41581-021-00515-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-021-00515-2
This article is cited by
-
Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA
Signal Transduction and Targeted Therapy (2024)